Targeting the Fas/FasL signaling pathway in cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 1, 2012, Pages 85-101

  Villa Morales, María ^a   Fernández Piqueras, José ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Apoptosis; Combined therapy; Fas CD95; FasL CD95L; Resistance; Sensitization; Therapy.

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADENOVIRUS VECTOR; ADIPONECTIN:FAS LIGAND; ANTINEOPLASTIC AGENT; APO 010; AZACITIDINE; BATIMASTAT; BLEOMYCIN; CARBOPLATIN; CD40:FAS LIGAND; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ASSOCIATED PROTEIN 4:FAS LIGAND; DOXORUBICIN; ETOPOSIDE; FAS ANTIBODY; FAS ANTIGEN; FAS LIGAND; FC RECEPTOR:FAS LIGAND; FLUOROURACIL; GATAPARSEN; MEGAFASL; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PACLITAXEL; PRINOMASTAT; R 125224; RECOMBINANT FAS LIGAND; RECOMBINANT PROTEIN; SC40:FAS LIGAND; SEPANTRONIUM BROMIDE; SINGLE CHAIN FRAGMENT VARIABLE CD7:FAS LIGAND; TOPOTARGET; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; ATTENUATED BACTERIA; BACTERIUM; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG TARGETING; EPIGENETICS; GENE THERAPY; HUMAN; IMMUNOSURVEILLANCE; LIPID RAFT; LUNG NON SMALL CELL CANCER; NONHUMAN; PROTEIN STRUCTURE; REVIEW; SOLID TUMOR; UPREGULATION;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; FAS LIGAND PROTEIN; GENE THERAPY; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84855867670     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.628937     Document Type: Review

References (164)

1. Oehm A, Behrmann I, Falk W, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992;267:10709-15
2. Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993;268:10932-7 (Pubitemid 23162276)
3. Fas (TNF receptor superfamily, member 6). Available from: http://www.ensembl.org/Homo-sapiens/Gene/Summary? g=ENSG00000026103;r=10: 90729553-90775542 [Last accessed 6 October 2011]
4. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62 (Pubitemid 24131584)
5. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78 (Pubitemid 24006113)
6. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-76 (Pubitemid 24106378)
7. Fas ligand (TNF superfamily, member 6). Available from: http://www.ensembl. org/Homo-sapiens/Gene/Summary?g=ENSG00000117560;r=1: 172628154-172636014 [Last accessed 6 October 2011]
8. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777-83
9. Mitsiades N, Yu WH, Poulaki V, et al. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001;61:577-81 (Pubitemid 32128617)
10. Ehrenschwender M, Wajant H. The role of FasL and Fas in health and disease. Adv Exp Med Biol 2009;647:64-93
11. Papoff G, Hausler P, Eramo A, et al. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem 1999;274:38241-50 (Pubitemid 30026900)
12. Algeciras-Schimnich A, Shen L, Barnhart BC, et al. Molecular ordering of the initial signaling events of CD95. Mol Cell Biol 2002;22:207-20 (Pubitemid 33144269)
13. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death- inducing signaling complex. Cell 1996;85:817-27 (Pubitemid 26193033)
14. Medema JP, Scaffidi C, Kischkel FC, et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997;16:2794-804 (Pubitemid 27226216)
15. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789-95
16. Lee HO, Ferguson TA. Biology of FasL. Cytokine Growth Factor Rev 2003;14:325-35 (Pubitemid 36693151)
17. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
18. Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000;78:312-25
19. Villa-Morales M, Santos J, Perez-Gomez E, et al. A role for the Fas/FasL system in modulating genetic susceptibility to T-cell lymphoblastic lymphomas. Cancer Res 2007;67:5107-16 (Pubitemid 46997246)
20. Wajant H. CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat Res 2006;130:141-65
21. Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 2007;220:82-101 (Pubitemid 350045568)
22. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008;8:74-80
23. Inaba H, Komada Y, Li QS, et al. mRNA expression of variant Fas molecules in acute leukemia cells. Am J Hematol 1999;62:150-8 (Pubitemid 29521762)
24. Tawara M, Maeda T, Yamada Y, et al. Aberrant processing of Fas transcripts in adult T-cell leukemia: a possible role in tumor cell survival. Cancer Lett 2003;193:235-42 (Pubitemid 36432111)
25. van Doorn R, Dijkman R, Vermeer MH, et al. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res 2002;62:5389-92
26. Mullauer L, Gruber P, Sebinger D, et al. Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res 2001;488:211-31 (Pubitemid 32521033)
27. Villa-Morales M, Gonzalez-Gugel E, Shahbazi MN, et al. Modulation of the Fas-apoptosis-signalling pathway by functional polymorphisms at Fas, FasL and Fadd and their implication in T-cell lymphoblastic lymphoma susceptibility. Carcinogenesis 2010;31:2165-71
28. Wu J, Siddiqui J, Nihal M, et al. Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys 2010;508:185-91
29. Zhang B, Sun T, Xue L, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007;28:1067-73 (Pubitemid 47072192)
30. Gazin C, Wajapeyee N, Gobeil S, et al. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007;449:1073-7 (Pubitemid 350014604)
31. Jones CL, Wain EM, Chu CC, et al. Downregulation of Fas gene expression in Sezary syndrome is associated with promoter hypermethylation. J Invest Dermatol 2010;130:1116-25
32. Santourlidis S, Warskulat U, Florl AR, et al. Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma. Mol Carcinog 2001;32:36-43
33. Maecker HL, Yun Z, Maecker HT, Giaccia AJ. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002;2:139-48 (Pubitemid 41039114)
34. Park SM, Peter ME. microRNAs and death receptors. Cytokine Growth Factor Rev 2008;19:303-11
35. Peshes-Yaloz N, Rosen D, Sondel PM, et al. Up-regulation of Fas (CD95) expression in tumour cells in vivo. Immunology 2007;120:502-11 (Pubitemid 46365008)
36. Ivanov VN, Lopez Bergami P, Maulit G, et al. FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol 2003;23:3623-35 (Pubitemid 36539194)
37. Strand S, Vollmer P, van den Abeelen L, et al. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 2004;23:3732-6 (Pubitemid 38658442)
38. Lin WW, Hsieh SL. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol 2011;81:838-47
39. Schattenberg JM, Schuchmann M, Galle PR. Cell death and hepatocarcinogenesis: dysregulation of apoptosis signaling pathways. J Gastroenterol Hepatol 2011;26(Suppl 1):213-19
40. Tourneur L, Mistou S, Michiels FM, et al. Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene 2003;22:2795-804 (Pubitemid 36609593)
41. Fulda S, Kufer MU, Meyer E, et al. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865-77 (Pubitemid 32937956)
42. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, et al. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000;60:4315-19 (Pubitemid 32103601)
43. Blomberg J, Ruuth K, Santos D, Lundgren E. Acquired resistance to Fas/CD95 ligation in U937 cells is associated with multiple molecular mechanisms. Anticancer Res 2008;28(2A):593-9 (Pubitemid 351578898)
44. Gimenez-Bonafe P, Tortosa A, Perez-Tomas R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 2009;9:320-40
45. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5 (Pubitemid 27297457)
46. Wang L, Azad N, Kongkaneramit L, et al. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J Immunol 2008;180:3072-80
47. Huerta S, Heinzerling JH, Anguiano-Hernandez YM, et al. Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res 2007;142:184-94 (Pubitemid 47277413)
48. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev 2002;3:401-10 (Pubitemid 34685698)
49. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5 (Pubitemid 19196649)
50. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-9 (Pubitemid 23261761)
51. Rensing-Ehl A, Frei K, Flury R, et al. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995;25:2253-8
52. Kim SH, Bianco N, Menon R, et al. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol Ther 2006;13:289-300 (Pubitemid 43056894)
53. Scholz M, Cinatl J. Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals. Med Res Rev 2005;25:331-42 (Pubitemid 40489665)
54. Nishimura Y, Hirabayashi Y, Matsuzaki Y, et al. In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Int Immunol 1997;9:307-16 (Pubitemid 27084855)
55. Yoshida H, Watanabe K, Takahashi S, Ichikawa K. Protective effects of HFE7A, mouse anti-human/mouse Fas monoclonal antibody against acute and lethal hepatic injury induced by Jo2. Cytotechnology 2010;62:313-23
56. Haruyama H, Ito S, Miyadai K, et al. Humanization of the mouse anti-Fas antibody HFE7A and crystal structure of the humanized HFE7A Fab fragment. Biol Pharm Bull 2002;25:1537-45 (Pubitemid 39663666)
57. Nakayama J, Ogawa Y, Yoshigae Y, et al. A humanized anti-human Fas antibody, R-125224, induces apoptosis in type I activated lymphocytes but not in type II cells. Int Immunol 2006;18:113-24 (Pubitemid 43057042)
58. Saito-Yabe M, Yoshigae Y, Takasaki W, et al. Highly frequent anti-idiotype antibody in cynomolgus monkeys developed against mouse-derived regions of anti-Fas antibody humanized by complementarity determining region grafting. Br J Pharmacol 2009;158:548-57
59. Jung G, Grosse-Hovest L, Krammer PH, Rammensee HG. Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments. Cancer Res 2001;61:1846-8 (Pubitemid 32691997)
60. Herrmann T, Grosse-Hovest L, Otz T, et al. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 2008;68:1221-7 (Pubitemid 351272242)
61. Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its 52. proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187:1205-13 (Pubitemid 28189110)
62. Aoki K, Kurooka M, Chen JJ, et al. Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat Immunol 2001;2:333-7 (Pubitemid 33706344)
63. Holler N, Tardivel A, Kovacsovics-Bankowski M, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 2003;23:1428-40 (Pubitemid 36177050)
64. Krippner-Heidenreich A, Grunwald I, Zimmermann G, et al. Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol 2008;180:8176-83
65. Berg D, Lehne M, Muller N, et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 2007;14:2021-34 (Pubitemid 350131152)
66. Greaney P, Nahimana A, Lagopoulos L, et al. A Fas agonist induces high levels of apoptosis in haematological malignancies. Leuk Res 2006;30:415-26 (Pubitemid 43254963)
67. Rikhof B, van der Graaf WT, Meijer C, et al. Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL. Br J Cancer 2008;99:1600-6
68. Verbrugge I, Maas C, Heijkoop M, et al. Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation. Cell Death Differ 2010;17:551-61
69. Eisele G, Roth P, Hasenbach K, et al. APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro-oncol 2011;13:155-64
70. TopoTarget A/S. A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors. ClinicalTrials.gov 2007 Available from: http://clinicaltrials. gov/ct2/results?term=apo010 [Last accessed 6 October 2011]
71. Scanlan MJ, Raj BK, Calvo B, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 1994;91:5657-61 (Pubitemid 24174387)
72. Samel D, Muller D, Gerspach J, et al. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation. J Biol Chem 2003;278:32077-82 (Pubitemid 37048396)
73. Bremer E, ten Cate B, Samplonius DF, et al. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 2006;107:2863-70
74. Bremer E, Abdulahad WH, de Bruyn M, et al. Selective elimination of pathogenic synovial fluid T-cells from rheumatoid arthritis and juvenile idiopathic arthritis by targeted activation of Fas-apoptotic signaling. Immunol Lett 2011;138:161-8
75. Bremer E, ten Cate B, Samplonius DF, et al. Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Res 2008;68:597-604 (Pubitemid 351380089)
76. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629-36 (Pubitemid 46842700)
77. Orbach A, Rachmilewitz J, Parnas M, et al. CTLA-4. FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals. J Immunol 2007;179:7287-94
78. Assohou-Luty C, Gerspach J, Siegmund D, et al. A CD40- CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J Mol Med 2006;84:785-97 (Pubitemid 44328069)
79. Orbach A, Rachmilewitz J, Shani N, et al. CD40.FasL and CTLA-4.FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling. Am J Pathol 2010;177:3159-68
80. Wajant H, Gerspach J, Pfizenmaier K. Engineering death receptor ligands for cancer therapy. Cancer Lett 2011 [Epub ahead of print] doi:10.1016/j.canlet. 2010.12.019
81. Watermann I, Gerspach J, Lehne M, et al. Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death Differ 2007;14:765-74 (Pubitemid 46444514)
82. Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 1997;94:13862-7 (Pubitemid 28009675)
83. Hedlund TE, Meech SJ, Srikanth S, et al. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ 1999;6:175-82 (Pubitemid 29082306)
84. Ambar BB, Frei K, Malipiero U, et al. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum Gene Ther 1999;10:1641-8 (Pubitemid 29328208)
85. Candolfi M, Yagiz K, Foulad D, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res 2009;15:4401-14
86. Fecker LF, Schmude M, Jost S, et al. Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication-competent CD95L adenovirus. Exp Dermatol 2010;19:e56-66
87. Hyer ML, Sudarshan S, Schwartz DA, et al. Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther 2003;10:330-9 (Pubitemid 36423115)
88. Kodaira H, Kume A, Ogasawara Y, et al. Fas and mutant estrogen receptor chimeric gene: a novel suicide vector for tamoxifen-inducible apoptosis. Jpn J Cancer Res 1998;89:741-7 (Pubitemid 28401160)
89. Li X, Liu YH, Zhang YP, et al. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clin Cancer Res 2007;13:5463-73 (Pubitemid 47510374)
90. Morelli AE, Larregina AT, Smith-Arica J, et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of 86. the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J Gen Virol 1999;80:571-83 (Pubitemid 29101210)
91. Norris JS, Bielawska A, Day T, et al. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther 2006;13:1045-51 (Pubitemid 44760102)
92. Okuyama T, Fujino M, Li XK, et al. Efficient Fas-ligand gene expression in rodent liver after intravenous injection of a recombinant adenovirus by the use of a Cre-mediated switching system. Gene Ther 1998;5:1047-53 (Pubitemid 28401306)
93. Aoki K, Akyurek LM, San H, et al. Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy. Mol Ther 2000;1(6):555-65
94. Rubinchik S, Wang D, Yu H, et al. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol Ther 2001;4:416-26 (Pubitemid 33100279)
95. Sipo I, Hurtado Pico A, Wang X, et al. An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy. J Mol Med 2006;84:215-25 (Pubitemid 43291010)
96. Smith RC, Machluf M, Bromley P, et al. Spatial and temporal control of transgene expression through ultrasound-mediated induction of the heat shock protein 70B promoter in vivo. Hum Gene Ther 2002;13:697-706 (Pubitemid 34280484)
97. Ho MY, Sun GH, Leu SJ, et al. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma. Int J Cancer 2008;123:123-33
98. Ho IA, Ng WH, Lam PY. FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors. Mol Cancer 2010;9:270
99. Symes JC, Siatskas C, Fowler DH, Medin JA. Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells. Cancer Gene Ther 2009;16:439-52
100. Bernardes N, Seruca R, Chakrabarty AM, Fialho AM. Microbial-based therapy of cancer: current progress and future prospects. Bioeng Bugs 2010;1:178-90
101. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Inhibition of tumor growth using Salmonella expressing Fas ligand. J Natl Cancer Inst 2008;100:1113-16
102. Mahmood Z, Shukla Y. Death receptors: targets for cancer therapy. Exp Cell Res 2010;316:887-99
103. Raghavendra PB, Pathak N, Manna SK. Novel role of thiadiazolidine derivatives in inducing cell death through Myc-Max, Akt, FKHR, and FasL pathway. Biochem Pharmacol 2009;78:495-503
104. Heikaus S, Matuszek KS, Suschek CV, et al. Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L). J Cancer Res Clin Oncol 2008;134:689-95
105. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-57 (Pubitemid 34407029)
106. ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results? term=ABT-510 [Last accessed 6 October 2011]
107. Ebbinghaus S, Hussain M, Tannir N, et al. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 2007;13:6689-95 (Pubitemid 350206805)
108. Muller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998;188:2033-45 (Pubitemid 28562520)
109. Amoroso A, Hafsi S, Militello L, et al. Understanding rituximab function and resistance: implications for tailored therapy. Front Biosci 2011;16:770-82
110. Gordon N, Kleinerman ES. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv 2010;23:189-96
111. Almendro V, Ametller E, Garcia-Recio S, et al. The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin. PLoS One 2009;4:e4728
112. Bousserouel S, Kauntz H, Gosse F, et al. Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. Int J Oncol 2010;36:1485-90
113. ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results? term=ag3340 [Last accessed 6 October 2011]
114. ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results? term=bisphosphonates&cond=cancer [Last accessed 6 October 2011]
115. ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results? term=AE-941 [Last accessed 6 October 2011]
116. Bissett D, O'Byrne KJ, von Pawel J, et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005;23:842-9 (Pubitemid 46224184)
117. Heath EI, Burtness BA, Kleinberg L, et al. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs 2006;24:135-40 (Pubitemid 43723905)
118. Fizazi K, Lipton A, Mariette X, et al. Randomized Phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71
119. Lu C, Lee JJ, Komaki R, et al. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized Phase III trial. J Natl Cancer Inst 2010;102:859-65
120. Dorman G, Cseh S, Hajdu I, et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010;70:949-64
121. Ametller E, Garcia-Recio S, Pastor-Arroyo EM, et al. Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death. Cancer Biol Ther 2011;11:4-13
122. Huang CR, Jin ZX, Dong L, et al. Cisplatin augments FAS-mediated apoptosis through lipid rafts. Anticancer Res 2010;30:2065-71
123. Rebillard A, Jouan-Lanhouet S, Jouan E, et al. Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells. Eur J Cancer 2010;46:1445-55
124. Mollinedo F, de la Iglesia-Vicente J, Gajate C, et al. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res 2010;16:2046-54
125. Stel AJ, Ten Cate B, Jacobs S, et al. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J Immunol 2007;178:2287-95 (Pubitemid 46233427)
126. Huang L, Ramirez JC, Frampton GA, et al. Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor. Lab Invest 2011;91:1007-17
127. Lahiry L, Saha B, Chakraborty J, et al. Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells. Carcinogenesis 2010;31:259-68
128. Micheau O, Hammann A, Solary E, Dimanche-Boitrel MT. STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. Biochem Biophys Res Commun 1999;256:603-7 (Pubitemid 29301153)
129. Fulda S, Meyer E, Friesen C, et al. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 2001;20:1063-75 (Pubitemid 32238855)
130. Bivona TG, Hieronymus H, Parker J, et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011;471:523-6
131. Duiker EW, van der Zee AG, de Graeff P, et al. The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol 2010;116:549-55
132. Tsumuraya T, Ishikawa C, Machijima Y, et al. Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem Pharmacol 2011;81:713-22
133. Zhang G, Park MA, Mitchell C, et al. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 2008;14:5385-99
134. Pawar P, Ma L, Byon CH, et al. Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res 2009;15:1288-96
135. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010;10:561-74
136. Kelly RJ, Lopez-Chavez A, Citrin D, et al. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 2011;10:35
137. Boumber Y, Issa JP. Epigenetics in cancer: what's the future? Oncology (Williston Park) 2011;25:220-6; 228
138. van Noesel MM, van Bezouw S, Voute PA, et al. Clustering of hypermethylated genes in neuroblastoma. Genes Chromosomes Cancer 2003;38:226-33 (Pubitemid 37259639)
139. Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol 2011;147:443-9
140. Poulaki V, Mitsiades CS, McMullan C, et al. Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing. Invest Ophthalmol Vis Sci 2005;46:358-66 (Pubitemid 40041219)
141. ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results? term=azacitidine [Last accessed 6 October 2011]
142. ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results? term=decitabine [Last accessed 6 October 2011]
143. Park MA, Mitchell C, Zhang G, et al. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca2+de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res 2010;70:6313-24
144. Emanuele S, Lauricella M, Carlisi D, et al. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 2007;12:1327-38 (Pubitemid 46890392)
145. Gillenwater AM, Zhong M, Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 2007;6:2967-75 (Pubitemid 350206775)
146. Murakami T, Sato A, Chun NA, et al. Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J Invest Dermatol 2008;128:1506-16 (Pubitemid 351693204)
147. Watanabe K, Okamoto K, Yonehara S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 2005;12:10-18 (Pubitemid 40090024)
148. Imai T, Adachi S, Nishijo K, et al. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 2003;22(58):9231-42 (Pubitemid 38122035)
149. Aron JL, Parthun MR, Marcucci G, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003;102:652-8 (Pubitemid 36841988)
150. ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results? term=vorinostat [Last accessed 6 October 2011]
151. ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results? term=romidepsin%2C [Last accessed 6 October 2011]
152. Bouzar AB, Boxus M, Defoiche J, et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 2009;144:41-52
153. Lee WJ, Chen YR, Tseng TH. Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells. Oncol Rep 2011;25:583-91
154. Koshkina NV, Rao-Bindal K, Kleinerman ES. Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer 2011;117:3457-67
155. Geng L, Zhu B, Dai BH, et al. A let-7/Fas double-negative feedback loop regulates human colon carcinoma cells sensitivity to Fas-related apoptosis. Biochem Biophys Res Commun 2011;408:494-9
156. Suzuki Y, Kim HW, Ashraf M, Haider H. Diazoxide potentiates mesenchymal stem cell survival via NF-kappaB-dependent miR-146a expression by targeting Fas. Am J Physiol 2010;299:H1077-82
157. Chhabra R, Adlakha YK, Hariharan M, et al. Upregulation of miR-23a-27a-24-2 cluster induces caspase-dependent and -independent apoptosis in human embryonic kidney cells. PLoS One 2009;4:e5848
158. Sayed D, He M, Hong C, et al. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem 2010;285:20281-90
159. Schickel R, Park SM, Murmann AE, Peter ME. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell 2010;38:908-15
160. Liu Z, Liu R, Qiu J, et al. Combination of human Fas (CD95/Apo-1) ligand with adriamycin significantly enhances the efficacy of antitumor response. Cell Mol Immunol 2009;6:167-74
161. Villa-Morales M, Santos J, Fernandez-Piqueras J. Functional Fas (Cd95/Apo-1) promoter polymorphisms in inbred mouse strains exhibiting different susceptibility to gamma-radiation-induced thymic lymphoma. Oncogene 2006;25:2022-9
162. Loeder S, Drensek A, Jeremias I, et al. Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer 2010;126:2216-28
163. Nabors LB, Fiveash JB, Markert JM, et al. A Phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol 2010;67:313-19
164. Campbell NE, Greenaway J, Henkin J, et al. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 2010;12:275-83